Medical University Department, Division of General Internal and Emergency Medicine, Kantonsspital Aarau, Aarau, Switzerland; Medical Faculty of the University of Basel, Basel, Switzerland.
Medical Faculty of the University of Basel, Basel, Switzerland.
Ann Oncol. 2021 Aug;32(8):1025-1033. doi: 10.1016/j.annonc.2021.05.793. Epub 2021 May 19.
Nutritional support in patients with cancer aims at improving quality of life. Whether use of nutritional support is also effective in improving clinical outcomes requires further study.
In this preplanned secondary analysis of patients with cancer included in a prospective, randomized-controlled, Swiss, multicenter trial (EFFORT), we compared protocol-guided individualized nutritional support (intervention group) to standard hospital food (control group) regarding mortality at 30-day (primary endpoint) and other clinical outcomes.
We analyzed 506 patients with a main admission diagnosis of cancer, including lung cancer (n = 113), gastrointestinal tumors (n = 84), hematological malignancies (n = 108) and other types of cancer (n = 201). Nutritional risk based on Nutritional Risk Screening (NRS 2002) was an independent predictor for mortality over 180 days with an (age-, sex-, center-, type of cancer-, tumor activity- and treatment-) adjusted hazard ratio of 1.29 (95% CI 1.09-1.54; P = 0.004) per point increase in NRS. In the 30-day follow-up period, 50 patients (19.9%) died in the control group compared to 36 (14.1%) in the intervention group resulting in an adjusted odds ratio of 0.57 (95% CI 0.35-0.94; P = 0.027). Interaction tests did not show significant differences in mortality across the cancer type subgroups. Nutritional support also significantly improved functional outcomes and quality of life measures.
Compared to usual hospital nutrition without nutrition support, individualized nutritional support reduced the risk of mortality and improved functional and quality of life outcomes in cancer patients with increased nutritional risk. These data further support the inclusion of nutritional care in cancer management guidelines.
癌症患者的营养支持旨在提高生活质量。营养支持是否也能有效改善临床结局,尚需进一步研究。
在一项前瞻性、随机对照、瑞士多中心试验(EFFORT)中,我们对纳入的癌症患者进行了预先计划的二次分析,将基于方案的个体化营养支持(干预组)与标准医院饮食(对照组)进行了比较,主要终点为 30 天死亡率以及其他临床结局。
我们分析了 506 例以癌症为主要入院诊断的患者,包括肺癌(n=113)、胃肠道肿瘤(n=84)、血液恶性肿瘤(n=108)和其他类型的癌症(n=201)。基于营养风险筛查 2002(NRS 2002)的营养风险是 180 天死亡率的独立预测因素,NRS 每增加 1 分,死亡风险比(age-、sex-、center-、cancer-type-、tumor activity-和 treatment- 调整)为 1.29(95%CI 1.09-1.54;P=0.004)。在 30 天随访期间,对照组有 50 例(19.9%)患者死亡,干预组有 36 例(14.1%)患者死亡,调整后的优势比为 0.57(95%CI 0.35-0.94;P=0.027)。交互检验未显示死亡率在癌症亚组间存在显著差异。营养支持还显著改善了功能结局和生活质量指标。
与无营养支持的常规医院营养相比,针对营养风险增加的癌症患者,个体化营养支持可降低死亡率,并改善功能和生活质量结局。这些数据进一步支持将营养护理纳入癌症管理指南。